Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
Dow
Medtronic
AstraZeneca

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CITALOPRAM HYDROBROMIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Citalopram Hydrobromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00222820 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed Mental Health Intervention Research Center (MHIRC) Phase 4 2002-04-01 We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person’s mood and anxiety and how these features affect a person’s capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person’s personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00222820 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed University of Pittsburgh Phase 4 2002-04-01 We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person’s mood and anxiety and how these features affect a person’s capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person’s personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00363909 Citalopram in Treating Postmenopausal Women With Hot Flashes Completed National Cancer Institute (NCI) Phase 3 2006-11-01 RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women. PURPOSE: This randomized phase III trial is studying three different doses of citalopram to compare how well they work in treating postmenopausal women with hot flashes.
NCT00363909 Citalopram in Treating Postmenopausal Women With Hot Flashes Completed Alliance for Clinical Trials in Oncology Phase 3 2006-11-01 RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women. PURPOSE: This randomized phase III trial is studying three different doses of citalopram to compare how well they work in treating postmenopausal women with hot flashes.
NCT00667121 Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline Active, not recruiting National Cancer Institute (NCI) N/A 2008-03-01 RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.
NCT00667121 Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline Active, not recruiting Mayo Clinic N/A 2008-03-01 RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Citalopram Hydrobromide

Condition Name

Condition Name for Citalopram Hydrobromide
Intervention Trials
Healthy 5
Hot Flashes 2
Depression 2
Psychosocial Effects of Cancer and Its Treatment 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Citalopram Hydrobromide
Intervention Trials
Depression 4
Depressive Disorder 3
Hot Flashes 2
Depressive Disorder, Major 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Citalopram Hydrobromide

Trials by Country

Trials by Country for Citalopram Hydrobromide
Location Trials
United States 41
Canada 2
India 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Citalopram Hydrobromide
Location Trials
Pennsylvania 3
Georgia 2
Oklahoma 2
Ohio 2
North Dakota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Citalopram Hydrobromide

Clinical Trial Phase

Clinical Trial Phase for Citalopram Hydrobromide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Citalopram Hydrobromide
Clinical Trial Phase Trials
Completed 8
Recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Citalopram Hydrobromide

Sponsor Name

Sponsor Name for Citalopram Hydrobromide
Sponsor Trials
University of Pittsburgh 2
Torrent Pharmaceuticals Limited 2
National Cancer Institute (NCI) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Citalopram Hydrobromide
Sponsor Trials
Other 6
Industry 6
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Medtronic
Boehringer Ingelheim
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.